Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

Leukemia

Volumn 19, Issue 11, 2005, Pages 1929-1933

  Zwierzina, Heinz ^a   Suciu, S ^b   Loeffler Ragg, J ^a   Neuwirtova, R ^c   Fenaux, P ^d   Beksac, M ^e   Harousseau, J ^f   Nuessler, V ^g   Cermak, J ^c   Solbu, G ^b   Willemze, R ^h   de Witte, T ⁱ   Amadori, S ^j   Stryckmans, P ^k   Bron, D ^k   Louwagie, A ^l   Selleslag, D ^l   Peetermans, M ^m   Berneman, Z ^m   Coiffier, B ⁿ   Thyss, A ^o   Bourhis, J H ^p   Fiere D ^q   Zittoun, R ^r   Marie, J P ^r   Maraninchi, D ^s   Baumelou, E ^t   Lowenberg, B ^u   Sonnenveld, P ^u   Gerhartz, H ^g   Ribeiro, M ^v   Ben Bassat, I ^w   Labar, B ^x   Dardenne, M ^y   more..

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d UNIVERSITÉ PARIS 13   (France)

^e ANKARA UNIVERSITY   (Turkey)

^f HÔTEL DIEU   (France)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

^k JULES BORDET INSTITUTE   (Belgium)

^l General Hospital St Jan   (Belgium)

^m ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁿ CENTRE HOSPITALIER LYON SUD   (France)

^o CENTRE ANTOINE LACASSAGNE   (France)

^p INSTITUT GUSTAVE ROUSSY   (France)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r HÔTEL DIEU   (France)

^s INSTITUT PAOLI CALMETTES   (France)

^t FOCH HOSPITAL   (France)

^u ERASMUS MEDICAL CENTER   (Netherlands)

^v HOSPITAL DE SÃO JOÃO   (Portugal)

^w SHEBA MEDICAL CENTER   (Israel)

^x KBC Zagreb   (Croatia)

^y NONE

more..

Author keywords

Arabinoside; GM CSF; Interleukin 3; Low dose cytosine; Myelodysplastic syndrome; Phase III trial

Indexed keywords

CYTARABINE; INTERLEUKIN 3; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG FATALITY; DRUG FEVER; DRUG INDICATION; DRUG RESPONSE; FLU LIKE SYNDROME; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REMISSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 27644562303     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403934     Document Type: Article

References (18)

1. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
2. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497-501.
3. De Witte T, Suciu G, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukemia following MDS of more than 6 months duration. Leukemia 1995; 9: 1805-1811.
4. deWitte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS (AML-MDS). Blood 2001; 98: 2326-2331.
5. Visani G, Malagola M, Piccaluga PP, Isidori A. Low dose Ara-C for myelodysplastic syndromes: Is it still a current therapy? Leuk Lymphoma 2004; 45: 1531-1538.
6. Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989; 64: 1812-1818.
7. Miller KB, Kyungmann K, Morrison FS, Winter JN, Bennett JM, Neiman RS et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study. Ann Hematol 1992; 65: 162-168.
8. Mittermüller J, Kolb HJ, Gerhartz HH, Wilmanns W. In vivo differentiation of leukaemic blasts and effect of low dose AraC in a marrow grafted patient with leukaemic relapse. Br J Haematol 1986; 62: 757-762.
9. Layton DM, Mufti GJ, Lyons J, Janssen JWG, Bartram CR. Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy. N Engl J Med 1988; 318: 1468-1471.
10. Rossi H, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2002; 16: 310-315.
11. Gerhartz HH, Marcus R, Delmer A, Zwierzina H, Suciu S, Dardenne M et al. A randomized phase II study of low-dose cytosine arabinoside (LD-araC) plus granulocyte/macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 1994; 8: 16-23.
12. Geissler RG, Schulte P, Ganser A. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes. Int J Hematol 1997; 65: 339-354.
13. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M et al. Effects of recombinant human interleukin-3 on patients with myelodysplastic syndromes. Blood 1990; 76: 455-462.
14. Gerhartz H, Zwierzina H, Walther J, Fenaux P, Hayat M, Jacobs A et al. Interleukin-3 plus low dose cytosine arabinoside for advanced myelodysplasia: A pilot study. Cancer Invest 1996; 14: 4-8.
15. Kalbfleisch JD, Prentice RL. The Survival Analysis of Failure Time Data. 2nd edn. Wiley Series in Probabilities and Statistics. New Jersey, USA: Wiley Inter-Science, 2002.,
16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
17. Brackx B, Broeders L, Touw I, Lowenberg B. Blast colony-forming cells in myelodysplastic syndrome: Decreased potential to generate erythroid precursors. Leukemia 1993; 7: 75-77.
18. Mufti GJ, Stevens J, Oscier D, Hamblin TG. Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 1986; 59: 425-432.